[ Therapy of patients at high risk for vascular events: telmisartan, ramipril or a combination? ].
Düsing
R
R
Medizinische Klinik und Poliklinik I, Universitätsklinikum Bonn, Wilhelm Strasse 35-37, Bonn, Germany. duesing@uni-bonn.de
Nitschmann
S
S
D000368:Aged; D000799:Angioedema / Q000139:chemically induced; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D001562:Benzimidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D001565:Benzoates / Q000009:adverse effects* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D017257:Ramipril / Q000009:adverse effects* / Q000627:therapeutic use*; D018570:Risk Assessment; D012307:Risk Factors; D000077333:Telmisartan
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D001562:Benzimidazoles; D001565:Benzoates; D017257:Ramipril; D000077333:Telmisartan